Heat shock protein 90 as a potential drug target against surra

被引:5
|
作者
Rochani, Ankit K. [1 ]
Mithra, Chandan [1 ]
Singh, Meetali [1 ]
Tatu, Utpal [1 ]
机构
[1] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India
关键词
Surra; Hsp90; 17-AAG; Trypanosomiasis; Trypanosoma evansi; TRYPANOSOMA-BRUCEI-BRUCEI; HSP90; INHIBITORS; CHAPERONE; EVANSI; DIMINAZENE; DISCOVERY; CRUZI; DIFFERENTIATION; CYMELARSAN;
D O I
10.1017/S0031182014000845
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Trypanosomiasis is caused by Trypanosoma species which affect both human and animal populations and pose a major threat to developing countries. The incidence of animal trypanosomiasis is on the rise. Surra is a type of animal trypanosomiasis, caused by Trypanosoma evansi, and has been included in priority list B of significant diseases by the World Organization of Animal Health (OIE). Control of surra has been a challenge due to the lack of effective drugs and vaccines and emergence of resistance towards existing drugs. Our laboratory has previously implicated Heat shock protein 90 (Hsp90) from protozoan parasites as a potential drug target and successfully demonstrated efficacy of an Hsp90 inhibitor in cell culture as well as a pre-clinical mouse model of trypanosomiasis. This article explores the role of Hsp90 in the Trypanosoma life cycle and its potential as a drug target. It appears plausible that the repertoire of Hsp90 inhibitors available in academia and industry may have value for treatment of surra and other animal trypanosomiasis.
引用
收藏
页码:1148 / 1155
页数:8
相关论文
共 50 条
  • [1] Heat Shock Protein 90 as Therapeutic Target for CVDs and Heart Ageing
    Dabravolski, Siarhei A.
    Sukhorukov, Vasily N.
    Kalmykov, Vladislav A.
    Orekhov, Nikolay A.
    Grechko, Andrey V.
    Orekhov, Alexander N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (02)
  • [2] Heat Shock Protein 90 Inhibitors in Oncology
    Ozgur, Aykut
    Tutar, Yusuf
    CURRENT PROTEOMICS, 2014, 11 (01) : 2 - 16
  • [3] Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors
    Yamazaki, Shinji
    Shen, Zhongzhou
    Jiang, Ying
    Smith, Bill J.
    Vicini, Paolo
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (06) : 1285 - 1294
  • [4] Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica
    Shahinas, Dea
    Debnath, Anjan
    Benedict, Christan
    McKerrow, James H.
    Pillai, Dylan R.
    FRONTIERS IN MICROBIOLOGY, 2015, 6
  • [5] Heat Shock Proteins: A Potential Anticancer Target
    Sankhala, Kamalesh K.
    Mita, Monica M.
    Mita, Alain C.
    Takimoto, Chris H.
    CURRENT DRUG TARGETS, 2011, 12 (14) : 2001 - 2008
  • [6] Role of heat shock protein 90 as an antiviral target for swine enteric coronaviruses
    Zhao, Zhuangzhuang
    Zhang, Ya-Qing
    Xu, Ling-Dong
    Xiao, Lihua
    Feng, Yaoyu
    Wang, Bin
    Huang, Yao-Wei
    VIRUS RESEARCH, 2023, 329
  • [7] Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation
    Maehana, Takeshi
    Tanaka, Toshiaki
    Hashimoto, Kohei
    Kobayashi, Ko
    Kitamura, Hiroshi
    Masumori, Naoya
    CELL STRESS & CHAPERONES, 2022, 27 (04) : 337 - 351
  • [8] Heat Shock protein 90: Role in Enterovirus 71 Entry and Assembly and Potential Target for Therapy
    Tsou, Yueh-Liang
    Lin, Yi-Wen
    Chang, Hsuen-Wen
    Lin, Hsiang-Yin
    Shao, Hsiao-Yun
    Yu, Shu-Ling
    Liu, Chia-Chyi
    Chitra, Ebenezer
    Sia, Charles
    Chow, Yen-Hung
    PLOS ONE, 2013, 8 (10):
  • [9] Anti-influenza virus activity of benzo[d]thiazoles that target heat shock protein 90
    Lamut, Andraz
    Gjorgjieva, Marina
    Naesens, Lieve
    Liekens, Sandra
    Lillsunde, Katja-Emilia
    Tammela, Paivi
    Kikelj, Danijel
    Tomasic, Tihomir
    BIOORGANIC CHEMISTRY, 2020, 98
  • [10] Heat-Shock Protein 90 (Hsp90) as Anticancer Target for Drug Discovery: An Ample Computational Perspective
    Kumalo, Hezekiel M.
    Bhakat, Soumendranath
    Soliman, Mahmoud E.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 86 (05) : 1131 - 1160